The Emergence of Psilocybin in Psychiatry and Neuroscience

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 555 - 555

Published: April 9, 2025

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile. Emerging evidence supports efficacy conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, limited population diversity trials. Advances biosynthetic production optimized psychotherapeutic integration are necessary to ensure scalability accessibility. Future should focus long-term safety, dosing precision, neurobiological mechanisms refine therapeutic applications. provides critical foundation advancing evidence-based of psilocybin.

Language: Английский

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol

Wellcome Open Research, Journal Year: 2025, Volume and Issue: 9, P. 401 - 401

Published: April 22, 2025

Background Functional neurological disorder (FND) is a common cause of symptoms including seizures and movement disorders. It can be debilitating, associated with high health social care costs, have poor prognosis. magnetic resonance imaging (fMRI) has suggested FND multi-network disorder. Converging evidence suggests that other mechanisms dissociation, interoception, motor agency may abnormal in people FND. Psychedelics are currently under investigation for numerous neuropsychiatric disorders been shown to disrupt functional brain networks. Administering psychedelics will help us probe mechanistic theories the Protocol In this open-label neuroimaging study, we administer 25mg oral psilocybin psychological support chronic (target n = 24). Participants undergo resting-state task-based (Libet’s clock, measure agency) fMRI sequences which compared pre-post manner. Additional outcomes measures interoception (heartbeat tracking task), somatisation, illness perceptions, suggestibility, dissociation collected. Data on expectancy, preparedness, subjective experience psychedelic also gathered. followed up three months following administration. changes networks analysed using seed-based approaches, additional exploratory analysis take place. Discussion The study thought potentially underpin As first modern FND, it understand whether administration alongside might safe feasible patient population.

Language: Английский

Ethical Considerations Regarding Psychedelics for Clinical Pain Research

Journal of Pain Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 4357 - 4364

Published: Dec. 1, 2024

Psychedelics, substances with a long history of cultural and medicinal use, are experiencing resurgence in clinical research, particularly psychiatry. Despite their classification as Schedule I drugs, recent studies suggest therapeutic potential, treating refractory depression. With chronic pain representing major health concern few non-opioid treatment options available, psychedelics being explored alternative modalities. The National Institutes Health (NIH) now funds psychedelic marking shift from previous decades limited funding. However, ethical considerations loom large. Vulnerable populations, such those that impairs autonomy, require careful consideration by researchers risks benefits. Additionally, interested entities must navigate complex regulatory landscapes involving the United States Food Drug Administration (FDA) Enforcement (DEA) when considering pursuing possible research. Furthermore, transparent collaboration among stakeholders-patients, researchers, bodies-is crucial for participant safety successful Although number approaches can be taken, we posit stakeholders consider utilizing principal-based research ethics, comprised principles beneficence, justice, nonmaleficence, to guide process. Ultimately, balancing promise integrity is paramount. Careful planning, collaboration, adherence increase likelihood management progresses responsibly, offering hope patients while safeguarding well-being.

Language: Английский